The U.S. Preventive Services Task Force (USPSTF) is expanding its recommendation for HIV antiretrovirals because more options are available on the market, according to MedScape.
The guidance, published Aug. 22 in JAMA, updates the group's previous recommendation from 2019 to take into account the new options that have become available since the FDA approvals that included a long-acting injectable form.
In the original report, daily oral tenofovir disoproxil fumarate with emtricitabine was the only approved medication available, and the task force recommended it. Since then, two new regimens have been approved: daily oral tenofovir alafenamide with emtricitabine, and the long-acting injectable cabotegravir.
The task forcea volunteer group of experts in primary and preventative careis supporting all three options, and is recommending that clinicians use the most appropriate selection for patients at risk for HIV infection.
Recommendations from this group are particularly helpful for clinicians who may not see HIV as their area of expertise, says Carolyn Chu, MD, chief medical officer of the American Academy of HIV Medicine. "Hopefully, this will catch the eye of people who are not tracking all of the HIV updates," she said.